Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share, bringing the deal in at about $935 million. Jazz expands its cancer pipeline with the new acquisition’s lead candidate, dordaviprone ...
After hours: February 28 at 5:35:21 PM EST Loading Chart for SVCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback